GeoVax Labs, Inc. filed a current report on November 19, 2026, disclosing the resignation of Chief Financial Officer Mark W. Reynolds, the appointment of Anna Skowron as incoming CFO, and the termination of Chief Medical Officer Kelly T. McKee, M.D.

Key Highlights

  • CFO resignation: Mark W. Reynolds resigned as Chief Financial Officer, Corporate Secretary, principal financial officer, and principal accounting officer, effective 5:00 p.m. Eastern Time on November 13, 2026.
  • New CFO appointed: Anna Skowron, age 39, was appointed Chief Financial Officer, principal financial officer, and principal accounting officer, effective November 16, 2026.
  • Consulting structure: Skowron serves as a non-employee officer through BPC Consulting Ltd.; GeoVax will pay BPC $10,000 per month plus applicable taxes.
  • Interim CEO compensation formalized: Tyler O'Brien's Consulting Agreement, effective November 5, 2026, sets his compensation at $15,000 per month, payable on the first day of each month.
  • CMO terminated: Kelly T. McKee, M.D., was terminated as Chief Medical Officer on November 17, 2026, effective immediately.
  • Notice period obligation: Either party to both consulting agreements may terminate on 90 days' prior written notice; early termination by the company triggers payment of fees for the full notice period.

GeoVax Labs Undergoes Three Executive Leadership Changes in One Week

GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company based in Smyrna, Georgia, disclosed a series of leadership changes across its senior officer ranks. According to the filing, Mark W. Reynolds resigned from all officer roles on November 13, 2026, including his positions as Chief Financial Officer, Corporate Secretary, principal financial officer, and principal accounting officer. The company did not disclose a reason for the resignation.

The Board of Directors appointed Anna Skowron as CFO on November 14, 2026, with her role commencing November 16, 2026. Per the filing, Skowron, 39, has served as a Director of BPC Consulting Ltd. since September 2025, and currently holds fractional CFO roles at GridAI Technologies Corp. (since March 7, 2025), Powell Max Limited (since February 9, 2026), and BioRestorative Therapies, Inc. (since August 2026). From 2020 through June 2026, she served as Principal of Skowron Accounting Professional Corporation. She holds a Bachelor of Commerce degree from the University of Toronto, with a Specialist in Accounting and a Major in Economics.

Under the CFO Consulting Agreement with BPC Consulting Ltd., the filing states that Skowron will oversee accounting and financial reporting, including preparation of the company's periodic regulatory filings, and will report to the Chief Executive Officer and the Chairman of the Audit Committee. BPC is also eligible to receive a performance-based bonus upon successful completion of the annual Form 10-K and related year-end audit, in an amount to be mutually agreed before the audit commences. Separately, the filing confirmed the termination of Chief Medical Officer Kelly T. McKee, M.D., on November 17, 2026, effective immediately, with no further details provided.

What Was Disclosed

GeoVax Labs reported the resignation of its CFO, the appointment of a new interim CFO through a consulting firm at $10,000 per month, the formalization of its interim CEO's $15,000 per month consulting arrangement, and the immediate termination of its Chief Medical Officer, all occurring between November 13 and November 17, 2026.